Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis
解决子宫内膜异位症女性心血管疾病风险加速的机制和干预措施
基本信息
- 批准号:10545738
- 负责人:
- 金额:$ 76.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-05 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAffectAgeAtherosclerosisBiological MarkersBlood VesselsCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCaringCause of DeathChronicConjugated EstrogensDiseaseEndometriumEndotheliumEstradiolEstrogen ReceptorsEstrogensGNRH1 geneGoalsGonadotropin Hormone Releasing HormoneGonadotropin Releasing Hormone InhibitorGynecologicHealthHumanImpairmentInfertilityInflammationInflammation MediatorsInflammatoryInterventionLOX geneLectinLipoprotein ReceptorLow-Density LipoproteinsMeasuresMediatingMetabolismModelingNatureNitric OxideOralOutcomeOxidantsPainPeripheralPhysiciansPhysiologicalPhysiologyPre-Clinical ModelProcessProductionProliferatingReceptor ActivationReproductive EndocrinologyResearchRisk FactorsRoleScientistSelective Estrogen Receptor ModulatorsSeriesSignal TransductionSimvastatinSiteSymptomsSyndromeTestingTherapeutic InterventionTissuesUterine cavityVascular DiseasesVasodilationWomanbrachial arteryburden of illnesscardiovascular disorder riskchronic pelvic painclinically relevantcomorbiditycytokinedensityeffective interventioneffectiveness measureendometriosisendothelial dysfunctionepidemiologic dataexperienceexperimental studyimprovedin vivonoveloxidized LDL receptorsoxidized lipidreceptorreduce symptomsreproductivesalicylsalicylic acidscavenger receptorstandard caresystemic inflammatory responsetherapeutic target
项目摘要
Endometriosis and is a debilitating estrogen-dependent gynecological disorder deriving from the presence of
endometrium like tissue in sites outside the uterine cavity. Approximately 6-10% of women have endometriosis
and suffer from symptoms including chronic pelvic pain, pain during intercourse, infertility, and other co-
morbidities associated with systemic inflammation. The widespread nature of this disease extends to impact
overall health, including contributing to elevated risk of cardiovascular disease (CVD) --the leading cause of
death in women. Endometriosis and atherosclerotic CVD are both inflammation-induced diseases. Estrogen
exposure is beneficial for women from a CVD standpoint, but the standard of treatment for endometriosis
includes estrogen suppression. This creates a conundrum for the long-term management of CVD risk in women
with endometriosis. This proposal fills a significant gap in prior research into the role of inflammatory signaling,
CVD risk and effective interventions to mitigate cardiovascular comorbidities. Circulating oxidized lipids and
inflammatory cytokines that are elevated in women with endometriosis stimulate the ubiquitously expressed
scavenger lectin-like oxidized LDL receptor (LOX-1) on the vasculature resulting in pronounced endothelial
dysfunction, one of the earliest detectable indicators of increased CVD risk. Estrogen directly inhibits LOX-1-
dependent endothelial dysfunction and thus the standards of care for endometriosis treatment may be
exacerbating CVD risk. Our working model is that endometriosis-associated systemic inflammatory mediators
increase LOX-1 receptor activity and result in endothelial dysfunction. Our global hypothesis is that in women
with endometriosis increased CVD risk is the result chronic systemic inflammation inducing endothelial
dysfunction, mediated through LOX-1 receptor, and this CVD risk is exacerbated by standard estrogen
suppression treatments. In this application, we use a multipronged approach including in vivo and ex vivo human
physiological experiments to determine the role of inflammation and estrogen suppression on cardiovascular
specific outcomes in the setting of endometriosis. This series of studies in women with endometriosis will
delineate the roles of estradiol (Specific Aim 1) and systemic inflammation (Specific Aim 2) in endometriosis-
associated accelerated CVD risk. These studies will evaluate novel signaling mechanisms including the linkage
common to both CVD and endometriosis through the downstream activation of the ubiquitous scavenger receptor
LOX-1. We will also test the effects of two distinct interventions (Specific Aim 3) including the selective estrogen
receptor modulator bazedoxifene, and the statin simvastatin in mitigating CVD risk in women with endometriosis.
Our studies have the potential to identify clinically relevant therapeutic targets and interventions thus decreasing
CVD burden in women with endometriosis.
子宫内膜异位症是一种衰弱的雌激素依赖型妇科疾病,源于
子宫腔外部位的子宫内膜样组织。大约6%-10%的女性患有子宫内膜异位症
并出现慢性盆腔疼痛、性交疼痛、不孕不育等症状。
与全身炎症相关的病态。这种疾病的广泛性延伸到了影响
总体健康,包括增加心血管疾病(CVD)的风险--这是
女性的死亡。子宫内膜异位症和动脉粥样硬化性心血管疾病都是由炎症引起的疾病。雌激素
从心血管疾病的角度来看,暴露对女性是有益的,但治疗子宫内膜异位症的标准是
包括雌激素抑制。这给女性心血管疾病风险的长期管理带来了难题。
患有子宫内膜异位症。这一提议填补了先前关于炎症信号作用的研究的一个重大空白,
心血管疾病的风险和有效的干预措施,以减轻心血管并发症。循环氧化脂质和
子宫内膜异位症患者体内炎性细胞因子的升高刺激其普遍表达
清除剂凝集素样氧化低密度脂蛋白受体(LOX-1)在血管系统上的表达,导致明显的内皮细胞
功能障碍,这是心血管疾病风险增加的最早可检测指标之一。雌激素直接抑制LOX-1-
依赖性内皮功能障碍,因此治疗子宫内膜异位症的护理标准可能是
加剧了心血管疾病的风险。我们的工作模型是子宫内膜异位症相关的全身性炎症介质
增加LOX-1受体活性,导致内皮功能障碍。我们的全球假设是,在女性
随着子宫内膜异位症心血管风险的增加,慢性全身炎症诱导内皮细胞生长
通过LOX-1受体介导的功能障碍,这种心血管疾病的风险被标准雌激素加剧
抑制疗法。在这项应用中,我们使用了包括体内和体外人类在内的多管齐下的方法
确定炎症和雌激素抑制对心血管的作用的生理学实验
子宫内膜异位症的特殊结局。这一系列针对患有子宫内膜异位症的女性的研究将
描述雌激素(特异性目标1)和全身性炎症(特异性目标2)在子宫内膜异位症中的作用
相关的加速心血管疾病风险。这些研究将评估新的信号机制,包括连锁
通过无处不在的清道夫受体的下游激活而共同发生于心血管疾病和子宫内膜异位症
LOX-1。我们还将测试两种截然不同的干预措施(具体目标3)的效果,包括选择性雌激素。
受体调节剂巴多昔芬和他汀类药物辛伐他汀在降低子宫内膜异位症患者心血管风险中的作用。
我们的研究有可能确定临床相关的治疗靶点和干预措施,从而减少
子宫内膜异位症患者的心血管负担。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lacy M. ALEXANDER其他文献
Lacy M. ALEXANDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lacy M. ALEXANDER', 18)}}的其他基金
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis
解决子宫内膜异位症女性心血管疾病风险加速的机制和干预措施
- 批准号:
10838754 - 财政年份:2023
- 资助金额:
$ 76.68万 - 项目类别:
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis
解决子宫内膜异位症女性心血管疾病风险加速的机制和干预措施
- 批准号:
10340678 - 财政年份:2022
- 资助金额:
$ 76.68万 - 项目类别:
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis
解决子宫内膜异位症女性心血管疾病风险加速的机制和干预措施
- 批准号:
10631533 - 财政年份:2022
- 资助金额:
$ 76.68万 - 项目类别:
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis
解决子宫内膜异位症女性心血管疾病风险加速的机制和干预措施
- 批准号:
10749132 - 财政年份:2022
- 资助金额:
$ 76.68万 - 项目类别:
Essential Hypertension and Human Skin Blood Flow
原发性高血压与人体皮肤血流量
- 批准号:
7894731 - 财政年份:2009
- 资助金额:
$ 76.68万 - 项目类别:
Essential Hypertension and Human Skin Blood Flow
原发性高血压与人体皮肤血流量
- 批准号:
7505362 - 财政年份:2009
- 资助金额:
$ 76.68万 - 项目类别:
Essential Hypertension and Human Skin Blood Flow
原发性高血压与人体皮肤血流量
- 批准号:
8403964 - 财政年份:2009
- 资助金额:
$ 76.68万 - 项目类别:
Essential Hypertension and Human Skin Blood Flow
原发性高血压与人体皮肤血流量
- 批准号:
8150615 - 财政年份:2009
- 资助金额:
$ 76.68万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 76.68万 - 项目类别:
Research Grant